These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19229415)

  • 1. SYNTAX trial: analysis and clinical implications.
    Gomes WJ; Braile DM
    Rev Bras Cir Cardiovasc; 2008; 23(4):III-V. PubMed ID: 19229415
    [No Abstract]   [Full Text] [Related]  

  • 2. A commentary on Diabetic and non-diabetic patients with left main and/ or three-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents by Banning AP et al.
    Marx N
    Diab Vasc Dis Res; 2011 Apr; 8(2):173. PubMed ID: 21562069
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
    Räber L; Wohlwend L; Wigger M; Togni M; Wandel S; Wenaweser P; Cook S; Moschovitis A; Vogel R; Kalesan B; Seiler C; Eberli F; Lüscher TF; Meier B; Jüni P; Windecker S
    Circulation; 2011 Jun; 123(24):2819-28, 6 p following 2828. PubMed ID: 21646500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating the EXCEL hypothesis: a propensity score matched 3-year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score ≤32.
    Capodanno D; Caggegi A; Capranzano P; Cincotta G; Miano M; Barrano G; Monaco S; Calvo F; Tamburino C
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):936-43. PubMed ID: 21547994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To excel or to confirm? That is the question.
    Dangas G
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):944. PubMed ID: 21598346
    [No Abstract]   [Full Text] [Related]  

  • 8. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year outcomes of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: are they equally good (or bad)?
    Cutlip DE
    Circulation; 2011 Jun; 123(24):2779-81. PubMed ID: 21646497
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries.
    Head SJ; Holmes DR; Mack MJ; Serruys PW; Mohr FW; Morice MC; Colombo A; Kappetein AP;
    JACC Cardiovasc Interv; 2012 Jun; 5(6):618-25. PubMed ID: 22721656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-related outcomes after drug-eluting stent: should we "never mind" or "mind" the gap?
    Mehran R; Kini AS
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1260-1. PubMed ID: 21232719
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.
    Mikhail GW; Gerber RT; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Joshi AA; Baim DS; Colombo A
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1250-9. PubMed ID: 21232718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.
    Yarkoni A; Brodsky A; Sabapathy R; Pershad A
    Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revascularization of left main coronary artery disease.
    Lee MS; Faxon DP
    Cardiol Rev; 2011; 19(4):177-83. PubMed ID: 21646871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial.
    Morice MC; Serruys PW; Kappetein AP; Feldman TE; Ståhle E; Colombo A; Mack MJ; Holmes DR; Torracca L; van Es GA; Leadley K; Dawkins KD; Mohr F
    Circulation; 2010 Jun; 121(24):2645-53. PubMed ID: 20530001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry.
    Karjalainen PP; Ylitalo A; Airaksinen JK; Nammas W
    J Interv Cardiol; 2011 Feb; 24(1):1-8. PubMed ID: 21039884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with coronary artery disease with biodegradable polymer based paclitaxel-eluting Infinnium coronary stent system: results of 1-year clinical follow-up a single center experience.
    Vedat A; Selcuk G; Refik E; Onur E; Murat C; Burak CA; Murat G; Cemsid D
    Indian Heart J; 2009; 61(3):254-7. PubMed ID: 20503830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peeling-off labels mounting evidence for benefit of drug-eluting stents with off-label use.
    Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2007 Nov; 50(21):2037-8. PubMed ID: 18021869
    [No Abstract]   [Full Text] [Related]  

  • 19. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial.
    Verheye S; Agostoni P; Dawkins KD; Dens J; Rutsch W; Carrie D; Schofer J; Lotan C; Dubois CL; Cohen SA; Fitzgerald PJ; Lansky AJ
    JACC Cardiovasc Interv; 2009 Mar; 2(3):205-14. PubMed ID: 19463427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I indications for coronary artery bypass graft surgery: what is the appropriate therapy for patients with multivessel coronary disease?
    Dean LS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):622-3. PubMed ID: 19628184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.